BR112016009962A2 - superagonistas de ação prolongada de hormônio glicoproteico - Google Patents

superagonistas de ação prolongada de hormônio glicoproteico

Info

Publication number
BR112016009962A2
BR112016009962A2 BR112016009962A BR112016009962A BR112016009962A2 BR 112016009962 A2 BR112016009962 A2 BR 112016009962A2 BR 112016009962 A BR112016009962 A BR 112016009962A BR 112016009962 A BR112016009962 A BR 112016009962A BR 112016009962 A2 BR112016009962 A2 BR 112016009962A2
Authority
BR
Brazil
Prior art keywords
glycoprotein hormone
acting
long
superagonists
treating
Prior art date
Application number
BR112016009962A
Other languages
English (en)
Inventor
D Weintraub Bruce
Szkudlinski Mariusz
Original Assignee
Trophogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trophogen Inc filed Critical Trophogen Inc
Publication of BR112016009962A2 publication Critical patent/BR112016009962A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pregnancy & Childbirth (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)

Abstract

essa invenção fornece análogos de hormônios glicoproteicos superativos e de ação prolongada que demonstram bioatividade aumentada, tanto in vitro como in vivo, quando comparados com os seus homólogos de tipo selvagem. os análogos são particularmente úteis no tratamento de indivíduos com baixa expressão do receptor ou reatividade deficiente do receptor e para tratamento de qualquer condição associada à atividade de hormônios glicoproteicos.
BR112016009962A 2013-11-05 2014-11-05 superagonistas de ação prolongada de hormônio glicoproteico BR112016009962A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361900094P 2013-11-05 2013-11-05
PCT/US2014/064143 WO2015069777A1 (en) 2013-11-05 2014-11-05 Glycoprotein hormone long-acting superagonists

Publications (1)

Publication Number Publication Date
BR112016009962A2 true BR112016009962A2 (pt) 2017-12-05

Family

ID=53042038

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016009962A BR112016009962A2 (pt) 2013-11-05 2014-11-05 superagonistas de ação prolongada de hormônio glicoproteico

Country Status (12)

Country Link
US (1) US10544200B2 (pt)
EP (1) EP3065766A1 (pt)
JP (1) JP2017502079A (pt)
KR (1) KR20160101906A (pt)
CN (1) CN105873602A (pt)
AR (1) AR098314A1 (pt)
AU (1) AU2014346859B2 (pt)
BR (1) BR112016009962A2 (pt)
CA (1) CA2929561A1 (pt)
MX (1) MX2016005973A (pt)
RU (1) RU2016117119A (pt)
WO (1) WO2015069777A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112136985B (zh) * 2020-09-27 2023-02-03 黑龙江省中医药科学院 一种提高鹅绒质量促进鹅绒增长的复合型饲料及其制备方法
CN115053865B (zh) * 2022-06-27 2023-04-14 四川省畜牧科学研究院 一种高产蛋鸡新品种的培育方法
CN116819103B (zh) * 2023-08-28 2023-11-07 成都大熊猫繁育研究基地 一种大熊猫tsh酶联免疫检测方法及单克隆抗体

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196123A (en) 1978-11-20 1980-04-01 Eugenia Rosemberg Hybrid chorionic gonadotropin preparations and methods for stimulating ovulation using same
JPS6176421A (ja) 1984-04-03 1986-04-18 セロノ　ラボラトリ−ズ　インコ−ポレイテツド ***誘発方法およびインビトロ受精方法
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
ATE130194T1 (de) 1987-05-12 1995-12-15 Serono Pharm Praep Subkutane verabreichung des humanen choriongonadotropins.
US5017566A (en) 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
EP0386203A1 (en) 1988-09-01 1990-09-12 Applied Research Systems ARS Holding N.V. Methods for producing gonadotropin and tsh super-agonists
GB8901778D0 (en) 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
US6225449B1 (en) 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
EP0404458A3 (en) 1989-06-19 1992-03-04 Bunge (Australia) Proprietary Limited Ovine follicle stimulating hormone
WO1991016922A1 (en) 1990-05-08 1991-11-14 University Of Medicine & Dentistry Of New Jersey Analogs of glycoprotein hormones having altered immunological characteristics, efficacy and/or receptor specificity
CA2087965A1 (en) 1990-07-30 1992-02-01 Ajoy Chakrabarti Accumulation of amino acids and peptides into liposomes
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
JPH07507201A (ja) 1992-03-10 1995-08-10 ザ　ガバメント　オブ　ザ　ユナイテッド　ステイツ　オブ　アメリカ，アズ　レプリゼンテッド　バイ　ザ　セクレタリー，デパートメント　オブ　ヘルス　アンド　ヒューマン　サービシーズ 可変鋳型反応
US5604198A (en) 1994-05-12 1997-02-18 Poduslo; Joseph F. Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents
US6020473A (en) 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US7005505B1 (en) 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
US6596712B2 (en) 1996-04-26 2003-07-22 Genaera Corporation Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
US6361992B1 (en) 1996-05-08 2002-03-26 The United States Of America As Represented By The Department Of Health And Human Services Thyroid stimulating hormone superagonists
DE69637375T2 (de) 1996-05-08 2009-02-12 The United States Government As Represented By The Department Of Health And Human Services Glycoprotein hormone (tsh) superagonists
WO1998007832A1 (en) 1996-08-23 1998-02-26 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor d (vegf-d)
WO1998016630A1 (en) 1996-10-11 1998-04-23 The Texas A & M University System Methods for the generation of primordial germ cells and transgenic animal species
US6750044B1 (en) 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
US6485942B1 (en) 1997-02-14 2002-11-26 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
US6080912A (en) 1997-03-20 2000-06-27 Wisconsin Alumni Research Foundation Methods for creating transgenic animals
US6281408B1 (en) 1998-02-20 2001-08-28 Thomas Jefferson University Efficient method for production of compound transgenic animals
CA2344277A1 (en) 1998-09-22 2000-03-30 University Of Maryland, Baltimore Cystine knot growth factor mutants
NZ511119A (en) 1998-11-02 2004-04-30 Ludwig Inst Cancer Res Vascular endothelial growth factor-like protein from ORF virus NZ2 binds and activates mammalian VEGF receptor-2
EP1169053A1 (en) 1999-04-13 2002-01-09 Inhale Therapeutic Systems, Inc. Pulmonary administration of dry powder formulations for treating infertility
CA2373822A1 (en) 1999-05-20 2000-11-30 Scios Inc. Vascular endothelial growth factor variants
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US20020127652A1 (en) 2000-02-11 2002-09-12 Schambye Hans Thalsgard Follicle stimulating hormones
DE60235761D1 (de) 2001-08-01 2010-05-06 Univ Bristol Clifton Isoform des vegfs
US20070184023A1 (en) 2003-10-30 2007-08-09 Pharmexa A/S Method for down-regulation of vegf
AU2004287645A1 (en) 2003-11-06 2005-05-19 Compugen Ltd. Variants of human glycoprotein hormone alpha chain: compositions and uses thereof
US8067368B2 (en) 2004-01-27 2011-11-29 The Ohio State University Research Foundation Vascular endothelial growth factors and methods of their use
TW200538465A (en) * 2004-03-19 2005-12-01 Trophogen Inc Follicle stimulating hormone superagonists
WO2011075606A2 (en) 2009-12-18 2011-06-23 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
PT2880164T (pt) 2012-07-30 2019-06-05 Trophogen Inc Superagonistas de ação prolongada de hormonas glicoproteicas

Also Published As

Publication number Publication date
CA2929561A1 (en) 2015-05-14
EP3065766A1 (en) 2016-09-14
KR20160101906A (ko) 2016-08-26
CN105873602A (zh) 2016-08-17
AU2014346859A1 (en) 2016-05-12
US10544200B2 (en) 2020-01-28
WO2015069777A1 (en) 2015-05-14
RU2016117119A (ru) 2017-12-11
AU2014346859B2 (en) 2019-06-20
US20160264639A1 (en) 2016-09-15
JP2017502079A (ja) 2017-01-19
MX2016005973A (es) 2016-11-14
AR098314A1 (es) 2016-05-26

Similar Documents

Publication Publication Date Title
NI201700042A (es) Composiciones y métodos de uso para tratar trastornos metabólicos.
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
CL2014003465A1 (es) Anticuerpo que se une al receptor del factor de crecimiento epidérmico humano dimérico (hegfr) ; composición farmacéutica que lo comprende; y uso para tratar el cáncer.
CL2014003421A1 (es) Análogos de glucagón que exhiben actividad agonista en el receptor del péptido insulinotrópico dependiente de glusosa (gip): composición farmacéutica; y método para reducir el aumento de peso o inducir pérdida de peso, particularmente para el tratamiento de la obesidad.
EA201490070A1 (ru) Коантагонисты глюкагонового рецептора/glp-1-рецептора
CR20150296A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
PH12014502452A1 (en) Gip-glp-1 dual agonist compounds and methods
CL2014001994A1 (es) Polipeptido mimético de apelina sintéticos para el tratamiento e insuficiencia cardiaca; composicion farmacéutica que comprende dicho polipeptido.
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
MX2016008134A (es) Reguladores de nrf2.
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
BR112012020558A2 (pt) moduladores do receptor de androgênio e seus usos
BR112014002817A2 (pt) Uso de um polipeptídeo p62, ou de um ácido nucleico que codifica p62
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
DOP2014000114A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
BR112018006810A2 (pt) regimes de dosagem
BR112016022333A2 (pt) Sulfamidase modificada e produção da mesma
BR112016009962A2 (pt) superagonistas de ação prolongada de hormônio glicoproteico
NZ707016A (en) Glycoprotein hormone long-acting superagonists
PE20160121A1 (es) Formulaciones de factor viii recombinantes
BR112015024877A2 (pt) vacinas que compreendem polipeptídeos de leishmania para o tratamento e diagnóstico de leishmaniose
GT201600190A (es) Compuestos químicos
BR112017027132A2 (pt) reguladores do nrf2

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 4A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2486 DE 28-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI